Pfizer’s Mark Swindell discusses the integration of Wyeth’s vaccine business after the acquisition by Pfizer. As President of Vaccines, Mr. Swindell is helping to create a seamless process for melding the former Wyeth specialty business with Pfizer. One of the stated goals for the combined Pfizer is to become a top-tier biotherapeutics company by 2015. The company’s pipeline now includes a total of six vaccines and 27 biologics in development.
Filed Under:
Research & Development
